Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. … [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]

  2. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017. … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682]

  3. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor
  4. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  5. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    ™ (REGN-EB3, a cocktail of [atoltivimab], [odesivimab], and [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical trials. … However, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB

  6. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

  7. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    It is sold by Pfizer under the name Petinutin.

    Synonyms: N,2-Dimethyl-2-phenylsuccinimide, alpha-Methyl-alpha-phenyl N-methyl succinimide
  8. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    [A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns … Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.

  9. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  10. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.